Bipartisan senators are calling for a hearing into how the Medicare program could, or even should, cover an expensive new Alzheimer’s drug with questionable benefit.
Sens. Elizabeth Warren (D-Mass.) and Bill Cassidy (R-La.) want the Senate Finance Committee to examine the challenges facing Medicare that were brought about by the Food and Drug Administration’s (FDA) decision to approve Biogen’s Aduhelm.
…
Read the full article here.